Participation Form

We will notify the Study Coordinator for "A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation," on your behalf, that you would like to participate in this study.

Please fill out the form below and click "Submit" to send a notification request.

or Cancel

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.